DPDamian Palus

Damian Palus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Damian Palus has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In-Hospital Complications Associated with Mortality in Patients Hospitalized for COVID-19: A Prospective Single-Center Cohort Study

    by Damian Palus, Zbigniew Heleniak, Krzysztof Kuziemski, Krzysztof Grudziński, Tomasz Stefaniak, Alan Majeranowski, Michał Hoffmann

    Background and Objectives: We assessed associations of variables recorded within 24 h of admission and in-hospital complications with mortality in adults hospitalized for COVID-19. Materials and Methods: This prospective single-center cohort included 249 adults hospitalized in 2021. Four mortality classifiers underwent repeated cross-validation and 0.632+ bootstrap validation, a resampling method that combines apparent and out-of-bag performance while adjusting for overfitting. Separate logistic regressions evaluated mortality and acute kidney injury (AKI), with AKI specifications including or excluding baseline renal laboratory predictors. Results: In-hospital mortality was 22.5%. The 0.632+ bootstrap estimates of the area under the receiver operating characteristic curve were 0.862 for random forest, 0.769 for ridge logistic regression, 0.757 for linear discriminant analysis, and 0.552 for quadratic discriminant analysis. Higher lymphocyte count was associated with lower odds of death (odds ratio 0.237; 95% confidence interval 0.089–0.632). AKI, shock, and renal replacement therapy were associated with high conditional mortality. Conclusions: Admission-assessment variables provided exploratory prognostic information on in-hospital mortality in adults hospitalized for COVID-19. Sparse events, incomplete covariate information, and the single-center setting limit inference. Independent validation, calibration, and assessment of clinical benefit are required before implementation.

  • Open Access

    Low PHASES-Estimated Rupture Risk Among Patients Presenting with Ruptured Intracranial Aneurysms: A Retrospective Single-Centre Observational Study

    by Mateusz Krakowiak, Bartłomiej Kulesza, Cezary Grochowski, Barbara Maria Myszkowska, Damian Palus, Agnieszka Brzozowska, Paweł Sokal

    Background/Objectives: The PHASES score is widely used to estimate the 5-year rupture risk of unruptured intracranial aneurysms, yet many patients present with aneurysmal subarachnoid haemorrhage despite low calculated risk. This study aimed to characterise the demographic and aneurysm-related profile of patients with ruptured aneurysms classified as low risk by PHASES. Methods: This retrospective single-centre observational study included 243 consecutive patients with radiologically confirmed ruptured intracranial aneurysms treated between 2013 and 2021. PHASES scores and estimated 5-year rupture risks were calculated retrospectively. Age, sex, arterial hypertension, aneurysm size, location, and multiplicity were analysed using non-parametric statistical methods. Results: The mean PHASES score was 5.16 ± 3.43 points. An estimated 5-year rupture risk below 1% was assigned to 125 patients (51.44%), and 54 patients (22.22%) had PHASES scores of 0–2. Ruptured aneurysms measuring ≤7 mm occurred in 147 patients (60.49%), and 210 patients (86.42%) were younger than 70 years. Internal carotid artery aneurysms were the most frequent overall, whereas anterior communicating artery aneurysms had the smallest median diameter while remaining among the most common rupture sites. Arterial hypertension was associated with larger aneurysm diameter. Conclusions: Low PHASES-estimated risks were common in this cohort of patients presenting with aneurysm rupture. Because the study included no comparison group with unruptured aneurysms, it cannot assess PHASES calibration or predictive performance. PHASES should therefore be used as a population-based decision-support tool rather than a stand-alone predictor of individual rupture risk, with morphology, imaging findings, documented growth, and patient-specific factors incorporated into clinical assessment.

  • Open Access

    Endoscopic spine surgery: methodology and outcomes based on patient feedback

    by Mateusz Krakowiak, Damian Krystian Palus, Vishnu Prakash Mundayadan, Barbara Maria Myszkowska, Cezary Grochowski, Bartłomiej Kulesza, Ewelina Nadolska, Paweł Sokal

    Endoscopic spine surgery: methodology and outcomes based on patient feedback. Background: Endoscopic lumbar decompression (ELD) is emerging as a minimally invasive alternative to traditional microdiscectomy, potentially offer...

  • Open Access

    The role of serum tryptase in COVID-19 pathogenesis and its value as a prognostic marker: a single-center prospective cohort study

    by Alan Majeranowski, Damian Palus, Michał Hoffmann, Zbigniew Heleniak, Tomasz Stefaniak, Krzysztof Kuziemski

    Background: Dysregulated inflammation is central to COVID-19 pathogenesis. Mast cells (MCs) and their protease tryptase are implicated in tissue injury and vascular dysfunction, but the prognostic value of circulating tryptase in COVID-19 remains uncertain. Methods: We conducted a prospective cohort study including 82 patients with laboratory-confirmed COVID-19 admitted between January and March 2021. On admission, serum tryptase, C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), and lymphocyte counts were measured. The objective of this study was to assess whether serum tryptase levels measured upon hospital admission are associated with COVID-19 severity and in-hospital mortality. Statistical analyses comprised t-tests, Mann–Whitney U tests, χ 2 tests, receiver operating characteristic (ROC) curve analysis, and logistic regression. Results: Serum tryptase levels at admission did not differ significantly between patients requiring oxygen and those who did not (mean 5.45 vs. 4.97 μg/L; p = 0.2906) or between survivors and non-survivors (mean 5.24 vs. 5.60 μg/L; p = 0.6486). ROC analysis confirmed limited prognostic performance for tryptase regarding oxygen requirement (AUC = 0.580; p = 0.2972) and mortality (AUC = 0.538; p = 0.6103). By contrast, CRP, PCT, and LDH correlated strongly with disease severity. Elevated PCT (p = 0.0016) and LDH (p = 0.0360) were significantly associated with mortality. Logistic regression showed no independent association between tryptase and adverse outcomes. Conclusion: In this prospective cohort, serum tryptase measured at admission was not associated with COVID-19 severity or mortality, suggesting limited utility as a prognostic biomarker. Established markers, particularly PCT and LDH, outperformed tryptase in predicting adverse clinical outcomes. The negative findings are clinically relevant as they demonstrate that tryptase does not contribute to prognostic risk stratification in COVID-19, and its measurement does not provide added value beyond standard inflammatory biomarkers.


  • Open Access

    Prognosis of patients with a history of organ transplantation during active COVID-19 infection

    by Piątek-Dalewska Olga, Kuziemski Krzysztof, Petra M. Grešner, Zielińska Alicja, Stefaniak Tomasz, Gołębiewska Martyna, Palus Damian

    Solid organ transplant recipients were among the most vulnerable groups during the COVID-19 pandemic. Chronic immunosuppression and multiple comorbidities

  • Open Access

    Association of pre-existing comorbidities and complications with inpatient COVID-19 mortality — a single-center retrospective study

    by Damian Palus, Martyna Gołębiewska, Olga Piątek-Dalewska, Krzysztof Grudziński, Krzysztof Kuziemski, Radosław Owczuk, Michał Hoffmann, Dariusz Kozłowski, Tomasz Stefaniak

    Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors


  • Open Access

    Analysing COVID treatment outcomes in dedicated wards at a large university hospital in northern Poland. A result-based observational study

    by Damian Krystian Palus, Martyna Ewa Gołębiewska, Olga Piątek, Alan Majeranowski, Radosław Owczuk, Krzysztof Kuziemski, Tomasz Stefaniak

    Introduction: Presenting outcomes of patients hospitalised for coronavirus disease (COVID-19) should be put in context and comparison with other facilities. Number of statistical parameters can be used to compare effectiveness of treatment, however varied methodology applied in studies can impede or hinder a reliable comparison. The aim of this study is to present outcomes of COVID-19 treatment in our facility using simplest parameters allowing for intercenter comparison - case fatality ratio (CFR), length of stay (LOS) and transparent patients’ characteristics, and to discuss factors affecting mortality in COVID-19. Methods: The data were collected from patients hospitalized in COVID-19 general and ICU isolation wards in the University Clinical Centre (UCC) in Gdansk, Poland, from November 2020 to June 2021, using a computer-based patient record system. The group consisted of 642 patients – 144 (39,1 %) were women and 391 (60,9 %) were men, with a median age of 69 (IQR 59-78) years. Values of LOS and CFR were calculated and analysed. Results: Overall CFR for the analysed period was 24,8 %, varying from 19,9 % in January to May 2021 to 33,8 % in November to December 2020. CFR was 18,9 % in general ward and 70,7 % in ICU. All ICU patients required intubation and mechanical ventilation, and forty-four (75,9 %) of them developed acute respiratory distress syndrome (ARDS). Average length of stay was 13,1 (± 7,1) days. Conclusion: CFR in the general ward in UCC was analogous to published outcomes, but higher in our ICU ward. It resulted from more rigorous ICU admittance criteria in UCC compared to other facilities, which corresponds with patients’ severe clinical condition and unfavourable prognosis. Heterogeneity of methods assessing initial clinical condition in different facilities makes a meaningful intercenter comparison challenging. In this study, we propose simple and transparent statistical and clinical parameters applicable in an intercenter analysis. What is already known on this topic - the outbreak of global pandemic caused by novel coronavirus SARS-CoV-2 has strained healthcare systems all over the world. Healthcare workers faced new challenges, as organisational, structural, and personal flaws were unearthed in the process. In subsequent waves the number of hospitalisations increased together with the death number in the ICUs. As we come to terms with a new disease, numerous studies reports, analyse and assess COVID-19 treatment outcomes What this study adds - COVID-19 treatment outcomes in ICU in our facility contrast with most of the published reports. We analyse the influence of some commonly omitted under-examined factors and propose simple and applicable parameters to compare results, such as CFR and LOS, enabling a meaningful intercenter comparison. How this study might affect research, practice, or policy - inclusion of CFR and LOS in studies on COVID-19 would remove significant bias and enable more robust evaluation of therapeutic interventions and outcomes. In this study we also discuss heterogeneity of admission criteria and show how their influence on treatment outcomes.

  • Open Access

    COVID-19-associated severe immune thrombocytopenia

    by Damian Palus, Alan Majeranowski, Andrzej Mital, Aleksandra Cegła, Michał Czarnogórski, Krzysztof Kuziemski

    The novel coronavirus disease (COVID-19) is not only a disease that affects the respiratory system but also a systemic disease resulting in various symptoms and complications. Haematological changes are common in patients with COVID-19 but reports of severe immune thrombocytopenia (IT) in patients with COVID-19 are rare. Hereby a case is presented of a 72-year-old male patient who developed severe, symptomatic IT a month after COVID-19. Thereinafter, aetiology, pathophysiology, diagnosis as well as treatment options were widely discussed. The novel coronavirus disease (COVID-19) is not only a disease that affects the respiratory system but also a systemic disease resulting in various symptoms and complications. Haematological changes are common in patients with COVID-19 but reports of severe immune thrombocytopenia (IT) in patients with COVID-19 are rare. Hereby a case is presented of a 72-year-old male patient who developed severe, symptomatic IT a month after COVID-19. Thereinafter, aetiology, pathophysiology, diagnosis as well as treatment options were widely discussed.